Spring Bank Pharmaceuticals (NASDAQ:SBPH) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued on Friday. The firm currently has a $12.00 price objective on the stock. Zacks Investment Research‘s price target points to a potential upside of 14.94% from the stock’s current price.

According to Zacks, “Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid chemistry platform. The company is developing SB 9200, for the treatment of viral diseases, including hepatitis B virus. Spring Bank Pharmaceuticals, Inc. is based in Hopkinton, United States. “

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald set a $34.00 price target on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 7th. Chardan Capital set a $45.00 price target on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 30th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $28.80.

Shares of NASDAQ:SBPH opened at $10.44 on Friday. The stock has a market cap of $172.09 million, a P/E ratio of -5.58 and a beta of 0.80. Spring Bank Pharmaceuticals has a 12 month low of $8.14 and a 12 month high of $15.73.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.17. On average, equities analysts predict that Spring Bank Pharmaceuticals will post -2.17 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. Rhumbline Advisers bought a new position in Spring Bank Pharmaceuticals during the 3rd quarter valued at about $122,000. Blair William & Co. IL bought a new position in Spring Bank Pharmaceuticals during the 3rd quarter valued at about $123,000. JPMorgan Chase & Co. grew its holdings in Spring Bank Pharmaceuticals by 464.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 12,712 shares of the company’s stock valued at $153,000 after purchasing an additional 10,458 shares during the last quarter. Pegasus Asset Management Inc. bought a new position in Spring Bank Pharmaceuticals during the 4th quarter valued at about $195,000. Finally, Dimensional Fund Advisors LP bought a new position in Spring Bank Pharmaceuticals during the 4th quarter valued at about $206,000. Institutional investors own 43.18% of the company’s stock.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

See Also: What is a bull market?

Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.